HelixTalk - Rosalind Franklin University's College of Pharmacy Podcast

In this episode, we review guideline recommendations and recent evidence for secondary prevention of stroke, including risk factor modification, anticoagulant therapy (in patients with atrial fibrillation), and antiplatelet therapy (in patients with noncardioembolic stroke).

In this episode, we discuss the latest and the greatest updates regarding aspirin use in primary prevention and provide you with a summary of results from recently published primary literature.

In this episode we discuss the recent FDA approval of esketamine (Spravato) for the management of treatment resistant depression as an add on to oral antidepressant therapy. The agent is novel though so, too, may be its adverse effect profile and logistics of administration.

In this episode, we will review the pharmacology, efficacy, and safety of the most common NSAIDs on the market.

In this episode, we discuss the changes made in the American Diabetes Association's 2019 Standards of Diabetes Care guideline as well as updates in therapy recommendations per ADA and ESDA consensus statement published in Fall 2018.

In this episode, we take a deep dive into the use of stimulants and other medications for management of ADHD. After decades of use, technology has resulted in changes to how they are administered. Furthermore new agents have become available, but are they an improvement?

In this episode, we discuss IV fluids for hospitalized patients, including normal saline (0.9% NaCl) and lactated ringer's. In addition, we review the newest literature supporting the use of balanced crystalloids over normal saline from the SMART and SALT-ED trials.

In this episode, we are excited to have a special guest with us. Dr. Dyson Wake is Senior Clinical Specialist in Pharmacogenomics at NorthShore University HealthSystem's Center for Molecular Medicine here in Chicagoland and is here to explain the current and future applications of pharmacogenomics to the area of personalized medicine, as well as expose some misconceptions.

In this episode, we review some of the most important new recommendations from the 2018 ACC/AHA guidelines for the management of blood cholesterol.

In this episode, we will review the FDA's Unapproved Drugs Initiative and how it has impacted the availability and pricing of commonly used (but old) medications, such as colchicine and vasopressin.

In this episode, we will discuss a new class of medications for preventing migraines called CGRP antagonists, including an overview of their development, clinical efficacy, and future goals of further research in this area.

In this episode, we continue to review insulin therapy including dosing-related specifications, dosing adjustments, injection technique, patient counseling pearls, and the concept of a sliding scale.

In this episode, we discuss a broad overview of insulin topics ranging from the various types of insulins, dosage forms, brand/generic names, pharmacokinetic nuances, injection technique, and a wide variety of clinical pearls.

In this episode, we discuss vaccine related updates with our vaccine expert, Dr. Lauren Angelo. The updates discussed in this episode include the new shingles vaccine, the variety of influenza vaccines on the market, and several other updates.

In this episode, we will discuss the advantages and disadvantages of a rate versus rhythm control strategy for atrial fibrillation.

In this episode, we discuss the importance of accurately recognizing depressive symptoms in patients with kidney disease and provide review the limited available literature regarding treatment in this population. We then discuss guidelines to determine some of the best treatment options for this unique subgroup of patients.

In this episode, we take a closer look at deuteration, specifically involving the medication deutetrabenazine (discussed back in episode 76). We feature a guest contributor from our pharmacy sciences department who assists us as we look at the drug design aspects of this unique molecule and its implications for research moving forward.

In this episode, we discuss some ways APPE students not only survive, but excel in the APPE rotations.

In this episode, we will review the diagnosis and treatment of heparin-induced thrombocytopenia (HIT).

In this episode, we interview Kathleen Lynch, PharmD and Ciantel (Adair) Blyler, PharmD, coauthors of the New England Journal of Medicine article, published in March 2018, investigating the role of pharmacist-led interventions for blood pressure reduction in black barbershops.

In this episode, we interview Janeen Winnike, Dean of the Office of Students Affairs at the RFUMS College of Pharmacy, regarding transitions from a student life to a practitioner life. With her previous role as an HR official within a large community pharmacy chain, she offers some "do's and don'ts" for students transitioning into new practitioners.

In this episode, we discuss five clinical pearls about pulmonary embolism ranging from PE diagnosis, classification, and treatment. We specifically examine when and how alteplase is given for PE and its use with concurrent anticoagulation.

In this episode, we discuss two new agents (valbenazine and deutetrabenazine) -- the first of their kind to receive FDA approval to manage tardive dyskinesia most commonly associated with antipsychotic use.

In the previous episodes, we discussed how we should evaluate a patient's bleeding and clotting risks as well as looked at recommendation for management for various anticoagulants. In this episode, we will continue the discussion to management of antiplatelets as well as when to resume both antiplatelets and anticoagulants following a procedure.

In this episode, we will discuss some important factors to consider in management of various anticoagulants. We will also provide agent specific pharmacodynamic and pharmacokinetic based recommendations.